Is Unicycive Therapeutics, Inc. (UNCY) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 18.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.5% / 33% | 18.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 2.4% / 33% | 82.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 18.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 2.4% / 33% | 82.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -102.3% | |
| Return on Assets (ROA) | -44.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$29M |
| Free Cash Flow | -$29M |
| Total Debt | $773,000 |
| Debt-to-Equity | 0.7 |
| Current Ratio | 3.8 |
| Total Assets | $32M |
Price & Trading
| Last Close | $6.63 |
| 50-Day MA | $6.67 |
| 200-Day MA | $5.46 |
| Avg Volume | 537K |
| Beta | 1.8 |
|
52-Week Range
$3.71
| |
About Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Unicycive Therapeutics, Inc. (UNCY) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Unicycive Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Unicycive Therapeutics, Inc.'s debt ratio?
Unicycive Therapeutics, Inc.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.4%.
What are Unicycive Therapeutics, Inc.'s key financial metrics?
Unicycive Therapeutics, Inc. has a market capitalization of $137M. Return on equity stands at -102.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.